ANUHPHRNSEAnuh Pharma Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 6 Feb, 2026 · 18:28 IST

Anuh Pharma Q3 FY26 PAT up 30% YoY, revenue rises about 24%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.4%Reaction day
₹79.95
prior close
₹84.14
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+2.6%+0.8% vs market
Pharmaceuticals peers, median of 159sector+1.8%+1.7% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.3
10m
-1.0
15m
-1.4
30m
-1.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.4+2.6+0.8+1.8+1.7
Next day
+4.6+3.6+1.0+2.4+2.3
2d
+3.2+3.1+0.1+2.0+1.2
3d
+2.0+2.6-0.6+1.2+0.8
4d
+1.2+1.1+0.1+0.7+0.5
5d
+1.2+0.3+0.9+0.0+1.2
1w
-2.5+1.6-4.1+0.8-3.3
15d
-3.1-3.9+0.9-4.4+1.3
1m
-2.4-8.1+5.7-5.3+2.8
2m
-1.8-3.1+1.3-3.0+1.1
3m
+3.8+9.2-5.3+5.0-1.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Revenue from operations grew 23.6% YoY to Rs 19,717.81 lakhs in Q3 FY26 versus Rs 15,951.33 lakhs in Q3 FY25. PAT rose 30% YoY to Rs 1,345.10 lakhs. Adjusted EBITDA margin expanded to 12.18% from 10.14% YoY. For 9M FY26, revenue grew 22.9% YoY to Rs 56,954.02 lakhs, though 9M PAT dipped 15.8% to Rs 2,936.47 lakhs. Board also authorized KMPs to determine materiality of events under SEBI LODR.

Likely market impact

Strong Q3 with double-digit revenue and profit growth, margin expansion reflects operational strength; full-year picture mixed on 9M numbers.